Information Provided By: 
Fly News Breaks for May 26, 2017
SPLK
May 26, 2017 | 08:14 EDT
Maxim analyst Nehal Chokshi attributed Splunk's slowdown in year-over-year product revenue growth in Q1 to a sales hiring slowdown and leadership issues in the EMEA region. However, he said that the company's increase in its FY18 billings and revenue guidance likely indicates that the EMEA slowdown is only temporary. Chokshi, who views the reaction to the earnings report as a buying opportunity, keeps a Buy rating and $84 price target on Splunk.
News For SPLK From the Last 2 Days
SPLK
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
